CTSO has been granted a new patent
Oct 09, 2024, 10:35 PM
-20.09%
What does CTSO do
CytoSorbents, headquartered in Princeton, New Jersey, specializes in blood purification technology and critical care immunotherapy, employing 186 people since its IPO on June 17, 2005. Its flagship product, CytoSorb, addresses cytokine storms in critical illnesses, with additional products like VetResQ and various candidates under development.
CTSO filed a patent for "improved cancer immunotherapy treatments" on Fri, May 24, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.